{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:24Z","timestamp":1792510944234,"version":"4.5.0"},"reference-count":22,"publisher":"Scientific Scholar","issue":"02","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":156,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Many chemotherapeutic agents, especially taxanes, can induce peripheral neuropathy.<\/jats:p>\n                  <jats:p>Aim To evaluate the clinical characteristics of taxane-induced neuropathy (TIN) and determine the proper assessment tool for TIN in patients with breast cancer.<\/jats:p>\n                  <jats:p>Setting and Design Single-center, observational, prospective study.<\/jats:p>\n                  <jats:p>Methods and Material Forty-three patients with breast cancer treated with taxanes were prospectively enrolled. The reduced version of the Total Neuropathy Score (TNSr) was performed at baseline and 3 months after enrollment. TIN was diagnosed if the difference between the baseline and 3-month TNSr was greater than 1. In patients with TIN, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire\u2014 Chemotherapy-Induced Peripheral Neuropathy (20-item scale (EORTC-CIPN20) was also assessed 3 months after enrollment.<\/jats:p>\n                  <jats:p>Results Thirty-seven out of 43 (86.0%) patients were diagnosed with TIN. Sensory symptoms (64.9%) were the most frequent abnormality, followed by autonomic symptoms (54.1%). No patients reported motor symptoms or motor weakness. The TNSr sensory symptom score positively correlated with that of the EORTC-CIPN20. Nerve conduction studies showed reduced nerve conduction velocities and amplitudes after taxane treatment compared to those before chemotherapy in all tested nerves; however, only three (8.1%) patients had sural sensory nerve action potential amplitude outside normal limits.<\/jats:p>\n                  <jats:p>Conclusions TIN was predominantly sensory with normal nerve conduction studies which is the main feature of small fiber neuropathy. A combination scale comprising of a clinician-based scale and a patient-reported questionnaire and specialized tests for small nerve fibers should be considered as proper assessment tools to evaluate TIN.<\/jats:p>","DOI":"10.1055\/s-0041-1731100","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T12:37:48Z","timestamp":1630931868000},"page":"58-63","source":"Crossref","is-referenced-by-count":4,"title":["A Prospective Study of Taxane-Induced Neuropathy with Breast Cancer: Proper Assessment Tool for Taxane-Induced Neuropathy"],"prefix":"10.25259","volume":"10","author":[{"given":"Eun Hee","family":"Sohn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chungnam National University Hospital, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery and Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Sook","family":"Jung","sequence":"additional","affiliation":[{"name":"College of Nursing, Chungnam National University, Daejeon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je Ryong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery and Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"R Zajaczkowska","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"S B Park","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy","volume":"19","author":"A Molassiotis","year":"2019","journal-title":"BMC Cancer"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"M Seretny","year":"2014","journal-title":"Pain"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"A Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"G Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1529-8027.2011.00351.x","article-title":"Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale","volume":"16","author":"B Frigeni","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"08","key":"ref8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"T J Postma","year":"2005","journal-title":"Eur J Cancer"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1188\/17.ONF.580-588","article-title":"The content validity of a chemotherapy-induced peripheral neuropathy patient-reported outcome Measure","volume":"44","author":"E M Lavoie Smith","year":"2017","journal-title":"Oncol Nurs Forum"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"Italian NETox Group. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale","volume":"12","author":"G Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jns.12140","article-title":"Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc(\u00a9)) in patients with chemotherapy-induced peripheral neuropathy","volume":"20","author":"D Binda","year":"2015","journal-title":"J Peripher Nerv Syst"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00520-017-3772-y","article-title":"IN FOCUS Delphi working party. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey","volume":"25","author":"J M McCrary","year":"2017","journal-title":"Support Care Cancer"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ene.12353","article-title":"Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies","volume":"21","author":"T Kr\u00f8ig\u00e5rd","year":"2014","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10549-017-4230-8","article-title":"Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients","volume":"164","author":"S M Monfort","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire","volume":"22","author":"E M Lavoie Smith","year":"2013","journal-title":"Qual Life Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"N Kerckhove","year":"2017","journal-title":"Front Pharmacol"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"N P Staff","year":"2017","journal-title":"Ann Neurol"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1007\/s00520-019-04781-6","article-title":"Chemotherapy-induced peripheral neuropathy-patient- reported outcomes compared with NCI-CTCAE grade","volume":"27","author":"A C Tan","year":"2019","journal-title":"Support Care Cancer"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2008.01.008","article-title":"Peripheral nerve damage associated with administration of taxanes in patients with cancer","volume":"66","author":"A A Argyriou","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clbc.2011.03.006","article-title":"Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach","volume":"11","author":"K Carlson","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","article-title":"Italian NETox Group. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity","volume":"11","author":"G Cavaletti","year":"2006","journal-title":"J Peripher Nerv Syst"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"131\u2013140","DOI":"10.1093\/jnci\/djx140","article-title":"Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review","volume":"110","author":"D R Rivera","year":"2018","journal-title":"J Natl Cancer Inst"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1731100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:24Z","timestamp":1781176344000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/a-prospective-study-of-taxane-induced-neuropathy-with-breast-cancer-proper-assessment-tool-for-taxane-induced-neuropathy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":22,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,9,23]]},"published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1731100","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}